Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions
International Journal of Molecular Sciences · 18.08.2023 · 24 (16) · 12931
DOI: 10.3390/ijms241612931 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.08.2023. Verfasst von Nguyễn Thị Thanh Nhàn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Neoplasms, Surgery, Computer-Assisted. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 377 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NIBIB NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Peptide-based strategies have received an enormous amount of attention because of their specificity and applicability. Their specificity and tumor-targeting ability are applied to diagnosis and treatment for cancer patients. In this review, we will summarize recent advancements and future perspectives on peptide-based strategies for cancer treatment. The literature search was conducted to identify relevant articles for peptide-based strategies for cancer treatment. It was performed using PubMed for articles in English until June 2023. Information on clinical trials was also obtained from ClinicalTrial.gov. Given that peptide-based strategies have several advantages such as targeted delivery to the diseased area, personalized designs, relatively small sizes, and simple production process, bioactive peptides having anti-cancer activities (anti-cancer peptides or ACPs) have been tested in pre-clinical settings and clinical trials. The capability of peptides for tumor targeting is essentially useful for peptide–drug conjugates (PDCs), diagnosis, and image-guided surgery. Immunomodulation with peptide vaccines has been extensively tested in clinical trials. Despite such advantages, FDA-approved peptide agents for solid cancer are still limited. This review will provide a detailed overview of current approaches, design strategies, routes of administration, and new technological advancements. We will highlight the success and limitations of peptide-based therapies for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology & Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL 60612, USA.
- Department of Surgery, Division of Surgical Oncology, University of Illinois College of Medicine, Chicago, IL 60612, USA.
- Richard & Loan Hill Department of Biomedical Engineering, University of Illinois College of Engineering, Chicago, IL 60607, USA.
- Department of Ophthalmology & Visual Sciences, University of Illinois College of Medicine, Chicago, IL 60612, USA.
ORCID-Profile: Nguyễn Thị Thanh Nhàn, Tohru Yamada, Kaori H Yamada
Förderung
- NEI NIH HHS
- NIBIB NIH HHS
- NCI NIH HHS
- National Institutes of Health/National Cancer Institute
- National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health/National Eye Institute
Zitieren
APA
Nhàn, N. T. T., Yamada, T., & Yamada, K. H. (2023). Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. International Journal of Molecular Sciences, 24(16), 12931. https://doi.org/10.3390/ijms241612931
Vancouver
Nhàn NTT, Yamada T, Yamada KH. Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. International Journal of Molecular Sciences. 2023;24(16):12931. doi:10.3390/ijms241612931
BibTeX
@article{Nhn2023,
author = {Nhàn, Nguyễn Thị Thanh and Yamada, Tohru and Yamada, Kaori H},
title = {Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {16},
pages = {12931},
doi = {10.3390/ijms241612931}
}
EUVIMED